Compare FFIN & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIN | BLCO |
|---|---|---|
| Founded | 1890 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.4B |
| IPO Year | 1994 | 2022 |
| Metric | FFIN | BLCO |
|---|---|---|
| Price | $35.25 | $16.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $36.50 | $18.45 |
| AVG Volume (30 Days) | ★ 896.0K | 340.4K |
| Earning Date | 04-16-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | ★ 13.46 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $17.16 | $8.65 |
| Revenue Next Year | $6.61 | $5.59 |
| P/E Ratio | $72.96 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $28.12 | $13.09 |
| 52 Week High | $38.13 | $18.92 |
| Indicator | FFIN | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 51.42 |
| Support Level | $31.30 | $15.36 |
| Resistance Level | $35.77 | $16.54 |
| Average True Range (ATR) | 0.76 | 0.48 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 49.62 | 23.23 |
First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.